Tötterman T H, Carlsson M, Funderud S, Simonsson B, Oberg G, Nilsson K
Clinical Immunology Section, University Hospital, Uppsala, Sweden.
Nouv Rev Fr Hematol (1978). 1988;30(5-6):279-81.
Two-color FACS analysis was used to study phenotypic subset and activation markers on circulating B (tumor) cells of 21 patients with chronic B-lymphocytic leukemia (B-CLL). Patients with clinically active (progressive) disease differed from patients with stable disease: B cells from the former patient category showed a significantly increased expression of the activation antigen 1D11 and FN99(CD9), and a decreased expression of the FN1 B subset marker. No clinical associations were observed using the CD23, CD25, 4F2, Ba, Bac-1 or FN50 markers. Functional studies showed that the B cells from both clinical categories of patients responded equally well with DNA synthesis when optimally triggered and supplied with T cell factors. However, B-CLL cells from patients with progressive disease secreted significantly higher levels of IgM in response to phorbol ester. The present experiments thus show that differences exist in the activation of B-CLL cells in vivo and that these patterns are correlated with disease activity. Further, the maximal in vitro proliferative capacity of individual tumor cells is similar, whereas differences in accessory T cell functions may exist between patients.
采用双色荧光激活细胞分选术（FACS）分析21例慢性B淋巴细胞白血病（B-CLL）患者循环B（肿瘤）细胞的表型亚群和激活标志物。临床活动（进展性）疾病患者与病情稳定患者不同：前一类患者的B细胞显示激活抗原1D11和FN99（CD9）表达显著增加，而FN1 B亚群标志物表达降低。使用CD23、CD25、4F2、Ba、Bac-1或FN50标志物未观察到临床相关性。功能研究表明，两类临床患者的B细胞在最佳触发并提供T细胞因子时，DNA合成反应同样良好。然而，进展性疾病患者的B-CLL细胞对佛波酯的反应分泌的IgM水平显著更高。因此，本实验表明体内B-CLL细胞的激活存在差异，且这些模式与疾病活动相关。此外，单个肿瘤细胞的最大体外增殖能力相似，而患者之间辅助性T细胞功能可能存在差异。
